Total Payments
$108,109
2024 Payments
$52,330
Companies
37
Transactions
632
Medicare Patients
1,166
Medicare Billing
$158,633
Payment Breakdown by Category
Other$83,272 (77.0%)
Food & Beverage$13,185 (12.2%)
Travel$11,491 (10.6%)
Education$161.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,272 | 26 | 77.0% |
| Food and Beverage | $13,185 | 572 | 12.2% |
| Travel and Lodging | $11,491 | 30 | 10.6% |
| Education | $161.39 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $91,670 | 160 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $7,188 | 7 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $1,412 | 78 | $0 (2024) |
| Alkermes, Inc. | $1,260 | 61 | $0 (2024) |
| Lundbeck LLC | $1,103 | 59 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $742.21 | 33 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $600.83 | 28 | $0 (2023) |
| ABBVIE INC. | $546.46 | 30 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $497.32 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $418.50 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52,330 | 159 | Teva Pharmaceuticals USA, Inc. ($50,113) |
| 2023 | $44,706 | 135 | Teva Pharmaceuticals USA, Inc. ($36,052) |
| 2022 | $6,494 | 92 | Teva Pharmaceuticals USA, Inc. ($5,043) |
| 2021 | $955.27 | 44 | Teva Pharmaceuticals USA, Inc. ($209.42) |
| 2020 | $189.64 | 12 | Lundbeck LLC ($60.95) |
| 2019 | $972.31 | 52 | Otsuka America Pharmaceutical, Inc. ($205.19) |
| 2018 | $1,214 | 74 | Otsuka America Pharmaceutical, Inc. ($215.47) |
| 2017 | $1,247 | 64 | Lundbeck LLC ($269.02) |
All Payment Transactions
632 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $15.41 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/17/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: Neurology | ||||||
| 12/17/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $1.92 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $27.27 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.39 | General |
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $115.74 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $130.07 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/27/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $18.01 | General |
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $182.96 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,420.00 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Travel and Lodging | Cash or cash equivalent | $962.46 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Travel and Lodging | Cash or cash equivalent | $825.72 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Travel and Lodging | Cash or cash equivalent | $277.11 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $103.00 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | Cash or cash equivalent | $34.12 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Central Nervous System | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Central Nervous System | ||||||
| 11/06/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 11/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: PSYCHIATRY | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $8.22 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 174 | 497 | $87,500 | $32,417 |
| 2022 | 7 | 328 | 752 | $119,500 | $46,485 |
| 2021 | 7 | 322 | 679 | $106,650 | $41,778 |
| 2020 | 9 | 342 | 741 | $94,270 | $37,954 |
Total Patients
1,166
Total Services
2,669
Medicare Billing
$158,633
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 122 | $22,325 | $9,487 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 81 | $16,200 | $5,798 | 35.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 19 | 96 | $14,400 | $4,752 | 33.0% |
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 18 | 44 | $11,000 | $4,036 | 36.7% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 28 | 76 | $9,175 | $3,528 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 34 | $4,200 | $1,803 | 42.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 14 | 14 | $4,200 | $1,619 | 38.6% |
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 15 | 30 | $6,000 | $1,394 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 118 | $22,450 | $9,017 | 40.2% |
| 99335 | Established patient custodial care facility, group care, or assisted living visit, typically 25 minutes | Office | 2022 | 57 | 118 | $17,700 | $7,056 | 39.9% |
| 99336 | Established patient custodial care facility, group care, or assisted living visit, typically 40 minutes | Office | 2022 | 29 | 74 | $14,800 | $6,782 | 45.8% |
| 99334 | Established patient custodial care facility, group care, or assisted living visit, typically 15 minutes | Office | 2022 | 64 | 137 | $13,700 | $4,892 | 35.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 96 | $14,400 | $4,702 | 32.7% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 27 | 82 | $11,100 | $4,061 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 52 | $6,500 | $2,937 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 18 | 41 | $8,200 | $2,599 | 31.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 17 | 17 | $5,100 | $2,271 | 44.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 17 | 17 | $5,550 | $2,166 | 39.0% |
| 99335 | Established patient assisted living visit, typically 25 minutes | Office | 2021 | 76 | 167 | $25,050 | $10,189 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 80 | $15,575 | $6,402 | 41.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 23 | 94 | $14,100 | $4,461 | 31.6% |
| 99334 | Established patient assisted living visit, typically 15 minutes | Office | 2021 | 66 | 118 | $11,800 | $4,116 | 34.9% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 23 | 68 | $9,950 | $3,344 | 33.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 19 | 19 | $6,300 | $3,014 | 47.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 40 | $8,000 | $3,012 | 37.6% |
About Dr. Subbu Sarma, MD
Dr. Subbu Sarma, MD is a Addiction Medicine healthcare provider based in Lees Summit, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2005. The National Provider Identifier (NPI) number assigned to this provider is 1689661829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Subbu Sarma, MD has received a total of $108,109 in payments from pharmaceutical and medical device companies, with $52,330 received in 2024. These payments were reported across 632 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($83,272).
As a Medicare-enrolled provider, Sarma has provided services to 1,166 Medicare beneficiaries, totaling 2,669 services with total Medicare billing of $158,633. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Addiction Medicine
- Location Lees Summit, MO
- Active Since 10/03/2005
- Last Updated 10/19/2021
- Taxonomy Code 2084A0401X
- Entity Type Individual
- NPI Number 1689661829
Products in Payments
- UZEDY (Drug) $85,518
- QUVIVIQ (Drug) $7,188
- AUSTEDO (Drug) $4,548
- REXULTI (Drug) $1,277
- ABILIFY MAINTENA (Drug) $924.08
- INGREZZA (Drug) $742.21
- VRAYLAR (Drug) $661.42
- ARISTADA (Drug) $640.62
- CAPLYTA (Drug) $466.03
- TRINTELLIX (Drug) $432.21
- Auvelity (Drug) $357.38
- Austedo XR (Drug) $337.24
- COBENFY (Drug) $328.44
- SPRAVATO (Drug) $299.87
- Aristada 441 mg (Drug) $289.61
- INVEGA SUSTENNA (Drug) $275.97
- LYBALVI (Drug) $257.79
- BELSOMRA (Drug) $242.64
- Trintellix (Drug) $238.00
- MYDAYIS (Drug) $218.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.